Research graph
References from HSV-1-Based Vectors for Gene Therapy of Neurological Diseases and Brain Tumors: Part II. Vector Systems and Applications. Local targets link to admitted publications; unresolved targets remain external evidence.
A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth
10.1016/0092-8674(81)90247-6 · 1981 · External reference
HSV-1 Vectors for Therapy of Experimental CNS Tumors
1999 · External reference
Rapid method for construction of recombinant HSV gene transfer vectors
10.1038/sj.gt.3300497 · 1997 · External reference
Engineering herpes simplex virus vectors for gene transfer to neurons
10.1038/nm0397-357 · 1997 · External reference
Transfer and expression of the IacZ gene in rat brain neurons mediated by herpes simplex virus mutants
1990 · External reference
Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4
10.1128/jvi.56.2.558-570.1985 · 1985 · External reference
Development and application of herpes simplex virus vectors for human gene therapy
10.1146/annurev.mi.49.100195.003331 · 1995 · External reference
Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1
10.1128/jvi.66.5.2952-2965.1992 · 1992 · External reference
Herpes simplex virus genes involved in latency in vitro
10.1099/0022-1317-68-12-3009 · 1987 · External reference
Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function
10.1128/jvi.68.10.6347-6362.1994 · 1994 · External reference
Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications
10.1038/sj.gt.3300755 · 1998 · External reference
Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons
10.1038/sj.gt.3300766 · 1998 · External reference
Replication-defective herpes simplex virus vectors for gene transfer in vivo
10.1073/pnas.93.21.11319 · 1996 · External reference
Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22
10.1128/jvi.70.9.6358-6369.1996 · 1996 · External reference
The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27
10.1128/jvi.71.6.4614-4625.1997 · 1997 · External reference
Repression of gene expression upon infection of cells with herpes simplex virus type 1 mutants impaired for immediate-early protein synthesis
10.1128/jvi.71.10.7807-7813.1997 · 1997 · External reference
Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression
10.1006/viro.1996.8424 · 1997 · External reference
Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins
10.1128/jvi.72.4.3307-3320.1998 · 1998 · External reference
Herpes simplex virus vector-mediated expression of bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo
10.1073/pnas.96.7.4078 · 1999 · External reference
Mapping of herpes simplex virus-1 neurovirulence to 34.5, a gene nonessential for growth in culture
10.1126/science.2173860 · 1990 · External reference
Replication, establishment of latency, and induced reactivation of herpes simplex virus 34.5 deletion mutants in rodent models
10.1172/jci116527 · 1993 · External reference
Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir
10.1227/00006123-199304000-00016 · 1993 · External reference
Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma
10.1073/pnas.92.5.1411 · 1995 · External reference
Gene delivery to the central and peripheral nervous systems of mice using HSVI ICP34.5 deletion mutant vectors
1996 · External reference
Delivery of a constitutively active form of the heat shock factor using a virus vector protects neuronal cells from thermal or ischaemic stress but not from apoptosis
10.1046/j.1460-9568.1998.00339.x · 1998 · External reference
Protection of neuronal cells from apoptosis by Hsp27 delivered with a herpes simplex virus-based vector
10.1074/jbc.274.8.5061 · 1999 · External reference
Gene delivery to rat enteric neurons using herpes simplex virus-based vectors
10.1007/bf02736851 · 1997 · External reference
Regulation and cell-typespecific activity of a promoter located upstream of the latencyassociated transcript of herpes simplex virus type 1
10.1128/jvi.64.7.3269-3279.1990 · 1990 · External reference
Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript
10.1128/jvi.64.10.5019-5028.1990 · 1990 · External reference
Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse
10.1073/pnas.86.19.7596 · 1989 · External reference
Utilization of the herpes simplex virus type 1 latency-associated regulatory region to drive stable reporter gene expression in the nervous system
10.1128/jvi.71.4.3197-3207.1997 · 1997 · External reference
Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice
10.1038/ng0892-379 · 1992 · External reference
A novel latencyactive promoter is contained within the herpes simplex virus type 1 UL flanking repeats
10.1128/jvi.68.4.2239-2252.1994 · 1994 · External reference
Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity
10.1128/jvi.73.1.519-532.1999 · 1999 · External reference
Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter
10.1007/bf00711459 · 1993 · External reference
In vivo expression of beta-galactosidase in hippocampal neurons by HSV-mediated gene transfer
10.1089/hum.1992.3.1-11 · 1992 · External reference
Long-term promoter activity during herpes simplex virus latency
10.1128/jvi.68.11.7148-7158.1994 · 1994 · External reference
Long-term expression of a foreign gene from a unique position in the latent herpes simplex virus genome
10.1089/hum.1996.7.12-1447 · 1996 · External reference
A latent, nonpathogenic HSV-1-derived vector stably expresses beta- galactosidase in mouse neurons
10.1016/0896-6273(90)90171-b · 1990 · External reference
Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy
1986 · External reference
Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system
10.1073/pnas.89.1.33 · 1992 · External reference
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-flu orocytosine/cytosine deaminase gene therapies
10.1093/jnci/90.5.370 · 1998 · External reference
Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication
10.1089/hum.1993.4.5-589 · 1993 · External reference
Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine
1996 · External reference
Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy
1995 · External reference
New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol
10.1089/hum.1998.9.9-1261 · 1998 · External reference
Experimental tumor therapy in mice using the cyclopho sphamide-activating cytochrome P450 2B1 gene
10.1089/hum.1994.5.8-969 · 1994 · External reference
Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo
10.1038/nm0596-567 · 1996 · External reference
Retrovirus-mediated wildtype p53 gene transfer to tumors of patients with lung cancer
10.1038/nm0996-985 · 1996 · External reference
Gene therapy for tumors of the central nervous system
10.1016/s1055-3207(18)30262-x · 1998 · External reference
Beta -galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus-infected mouse
10.1016/0042-6822(88)90079-7 · 1988 · External reference
Expanded spectrum of viral therapy in the treatment of nervous system tumors
10.3171/jns.1992.77.4.0590 · 1992 · External reference
Experimental therapy of human glioma by means of a genetically engineered virus mutant
10.1126/science.1851332 · 1991 · External reference
Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1
10.1093/jnci/86.16.1209 · 1994 · External reference
Toxicity studies in thymidine kinase-deficient herpes simplex virus therapy for malignant astrocytoma
10.3171/jns.1996.85.4.0662 · 1996 · External reference
Transcriptional targeting of herpes simplex virus for cell-specific replication
10.1128/jvi.71.7.5124-5132.1997 · 1997 · External reference
Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats
10.1007/bf01306455 · 1994 · External reference
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase
1994 · External reference
Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors
10.1089/hum.1994.5.2-183 · 1994 · External reference
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene
1994 · External reference
Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 IacZ insertion mutant
10.1128/jvi.62.1.196-205.1988 · 1988 · External reference
Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductasedeficient herpes simplex viral mutant
1994 · External reference
Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2
10.1099/0022-1317-75-9-2367 · 1994 · External reference
Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’ sequence
10.1099/0022-1317-72-3-631 · 1991 · External reference
Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours—evaluation of a potentially effective clinical therapy
10.1038/bjc.1996.431 · 1996 · External reference
Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
10.1038/nm0995-938 · 1995 · External reference
Therapeutic efficiency and safety of a second-generation replication-conditional HSVI vector for brain tumor gene therapy
10.1089/hum.1997.8.17-2057 · 1997 · External reference
A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors
10.1089/hum.1997.8.5-533 · 1997 · External reference
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors
1997 · External reference
Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant
1995 · External reference
Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS
10.1097/00005072-199612000-00010 · 1996 · External reference
Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant
10.1006/viro.1995.1382 · 1995 · External reference
Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy
10.1046/j.1365-2990.1998.00133.x · 1998 · External reference
Therapeutic replication-competent herpes virus
10.1038/nm0298-133c · 1998 · External reference
The range and distribution of murine central nervous system cells infected with the gamma(1)34.5-mutant of herpes simplex virus 1
10.1128/jvi.71.7.5560-5569.1997 · 1997 · External reference
A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system
10.1099/0022-1317-79-3-525 · 1998 · External reference
A gamma 34.5 mutant of herpes simplex 1 causes severe inflammation in the brain
10.1016/s0306-4522(97)00513-7 · 1998 · External reference
Potential and limitations of a gamma 34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNS
10.1038/sj.gt.3300639 · 1998 · External reference
Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice
10.3109/13550289809113487 · 1998 · External reference
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
10.1038/sj.gt.3300550 · 1998 · External reference
Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors
10.1038/sj.gt.3300546 · 1998 · External reference
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus
10.1097/00000658-199609000-00008 · 1996 · External reference
Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment
10.1089/hum.1996.7.16-1989 · 1996 · External reference
Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors
10.1089/hum.1996.7.3-291 · 1996 · External reference
Imaging HSV-1 vector replication and gene delivery in vivo
1999 · External reference
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
10.1038/nbt0598-444 · 1998 · External reference
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/CYP2B1 and ganciclovir/HSV-TK gene therapies
1999 · External reference
Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector
10.1038/sj.gt.3300643 · 1998 · External reference
Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1
10.1038/sj.gt.3300535 · 1997 · External reference
Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1
1995 · External reference
Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir
10.1128/aac.33.8.1395 · 1989 · External reference
Treatment of human breast cancer in a brain metastatic model by G207, a replicationcompetent multimutated herpes simplex virus 1
10.1089/hum.1998.9.15-2177 · 1998 · External reference
Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity
10.1089/10430349950018832 · 1999 · External reference
Act locally, think globally
10.1038/nm1297-1323 · 1997 · External reference
Anatomy of herpes simplex virus DNA
1976 · External reference
Structure and origin of defective genomes contained in serially passaged herpes simplex virus type 1 (Justin)
10.1128/jvi.29.3.1065-1077.1979 · 1979 · External reference
Structure and expression of class II defective herpes simplex virus genomes encoding infected cell polypeptide number 8
10.1128/jvi.43.2.574-593.1982 · 1982 · External reference
The herpes simplex virus amplicon. IV. Efficient expression of a chimeric chicken ovalbumin gene amplified within defective virus genomes
10.1016/0042-6822(85)90351-4 · 1985 · External reference
The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector
10.1016/0092-8674(82)90035-6 · 1982 · External reference
Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperaturesensitive mutant tsK
10.1128/jvi.29.1.275-284.1979 · 1979 · External reference
A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons
10.1126/science.2843986 · 1988 · External reference
A prominent serine-rich region in Vmw175, the major transcriptional regulator protein of herpes simplex virus type 1, is not essential for virus growth in tissue culture
10.1099/0022-1317-71-8-1775 · 1990 · External reference
Expression of an immediate early polypeptide and activation of a viral origin of DNA replication in cells containing a fragment of herpes simplex virus DNA
10.1016/0042-6822(85)90184-9 · 1985 · External reference
An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology
10.1073/pnas.87.22.8950 · 1990 · External reference
Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient
10.1128/jvi.63.1.18-27.1989 · 1989 · External reference
Evidence that the herpes simplex virus immediate early protein ICP27 acts posttranscriptionally during infection to regulate gene expression
10.1016/0042-6822(92)90062-t · 1992 · External reference
Generation of high-titer defective HSV-1 vectors using an IE 2 deletion mutant and quantitative study of expression in cultured cortical cells
10.2144/19962003460 · 1996 · External reference
Increased transcomplementation properties of plasmids carrying HSV-1 origin of replication and packaging signals
10.1006/viro.1996.0081 · 1996 · External reference
A novel ‘piggyback’ packaging system for herpes simplex virus amplicon vectors
10.1089/hum.1996.7.16-2003 · 1996 · External reference
Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas
10.1002/(sici)1521-2254(199905/06)1:3<176::aid-jgm35>3.0.co;2-t · 1999 · External reference
A cosmid-based system for constructing mutants of herpes simplex virus type 1
10.1006/viro.1993.1572 · 1993 · External reference
Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells
10.1128/jvi.70.10.7190-7197.1996 · 1996 · External reference
Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo
10.1097/00001756-199712010-00029 · 1997 · External reference
Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors
10.1007/bf03401718 · 1997 · External reference
HSV-1 Amplicon
1998 · External reference
HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells
10.1089/hum.1997.8.3-359 · 1997 · External reference
Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors
10.1089/hum.1998.9.18-2787 · 1998 · External reference
Herpes Simplex Virus Type 1-Based Amplicon and Hybrid Amplicon Vector Systems
1999 · External reference
An enhanced packaging system for helper-dependent herpes simplex virus vectors
10.1128/jvi.72.9.7137-7143.1998 · 1998 · External reference
Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene
10.1073/pnas.90.8.3655 · 1993 · External reference
Long-term expression in sensory neurons in tissue culture from herpes simplex virus type 1 (HSV-1) promoters in an HSV-1-derived vector
10.1128/jvi.69.8.4593-4599.1995 · 1995 · External reference
Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector
10.1089/hum.1996.7.16-2015 · 1996 · External reference
Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector
10.1073/pnas.91.19.8979 · 1994 · External reference
Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome
10.1128/jvi.71.4.3299-3306.1997 · 1997 · External reference
Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration
10.1165/ajrcmb.11.5.7946381 · 1994 · External reference
Characterization of a preferred site on human chromosome 19q for integration of adenoassociated virus DNA by non-homologous recombination
10.1002/j.1460-2075.1992.tb05614.x · 1992 · External reference
Site-specific integration by adeno-associated virus
10.1073/pnas.93.21.11288 · 1996 · External reference
Adeno-associated virus vectors preferentially transduce cells in S phase
10.1073/pnas.91.19.8915 · 1994 · External reference
Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome
10.1128/jvi.71.10.7951-7959.1997 · 1997 · External reference
Gene transfer to the nigrostriatal system by hybrid HSV/AAV amplicon vectors
1999 · External reference
The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication
10.1016/0092-8674(89)90433-9 · 1989 · External reference
Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1
10.1128/jvi.68.6.4067-4071.1994 · 1994 · External reference
Engineering a miniherpesvirus as a general strategy to transduce up to 180 kb of functional self-replicating human mini-chromosomes
1996 · External reference
Long-term gene expression from autonomously replicating vectors in mammalian cells
1996 · External reference
A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells
10.1073/pnas.81.12.3806 · 1984 · External reference
A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo
10.1128/jvi.70.12.8422-8430.1996 · 1996 · External reference
A novel herpesvirus amplicon system for in vivo gene delivery
10.1038/sj.gt.3300523 · 1997 · External reference
Single-step conversion of cells to retrovirus vector producers with HSV/EBV hybrid amplicons
10.1128/jvi.73.12.10426-10439.1999 · 1999 · External reference
HSV-1 vectormediated gene transfer of the human nerve growth factor receptor p75hNGFR defines high-affinity NGF binding
10.1523/jneurosci.13-03-00941.1993 · 1993 · External reference
Molecular analysis of the function of the neuronal growth-associated protein GAP-43 by genetic intervention
10.1007/bf02935542 · 1991 · External reference
Transsynaptic neuronal loss induced in hippocampal slice cultures by a herpes simplex virus vector expressing the GIuR6 subunit of the kainate receptor
10.1073/pnas.90.13.6165 · 1993 · External reference
Defective herpes simplex virus vectors expressing the rat brain glucose transporter protect cultured neurons from necrotic insults
10.1046/j.1471-4159.1995.65020842.x · 1995 · External reference
Defective HSV-1 vector expressing BDNF in auditory ganglia elicits neurite outgrowth: model for treatment of neuron loss following cochlear degeneration
10.1089/hum.1996.7.2-173 · 1996 · External reference
Defining responsiveness of avian cochlear neurons to brain-derived neurotrophic factor and nerve growth factor by HSV-1-mediated gene transfer
10.1046/j.1471-4159.1998.70062336.x · 1998 · External reference
Herpes simplex virus vectors overexpressing the glucose transporter gene protect against seizure-induced neuron loss
10.1073/pnas.92.16.7247 · 1995 · External reference
Over-expression of the glucose transporter gene with a herpes simplex viral vector protects striatal neurons against stroke
10.1097/00004647-199603000-00001 · 1996 · External reference
Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke
10.1097/00004647-199707000-00003 · 1997 · External reference
Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia
10.1161/01.str.26.9.1670 · 1995 · External reference
Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase
10.1126/science.266.5189.1399 · 1994 · External reference
Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of cre recombinase
10.1038/nbt0197-57 · 1997 · External reference
Introduction of a foreign gene (Escherichia coli IacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study
10.1016/0014-4886(92)90196-w · 1992 · External reference
Specific patterns of defective HSV-1 gene transfer in the adult central nervous system: implications for gene targeting
10.1006/exnr.1994.1192 · 1994 · External reference
Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects
10.1016/0165-0270(94)00150-f · 1995 · External reference
Effect of exogenous nerve growth factor on neurotoxicity of and neuronal gene delivery by a herpes simplex amplicon vector in the rat brain
10.1089/hum.1994.5.8-987 · 1994 · External reference
Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors
1994 · External reference
Immunological consequences of HSV-1-mediated gene transfer into the CNS
1994 · External reference
Gene delivery by helper virus-free defective herpes viral vectors
1999 · External reference
Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector
10.1016/s0165-0270(97)00207-0 · 1998 · External reference
Stereotactic intracerebral catheter implantation and continuous intratumoral infusion of the liposome associated HSV-tk gene inpatients with recurrent, unresectable glioblastoma multiforme-Clinical protocol for a phase I/II study
1998 · External reference
Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpres sion of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase
1998 · External reference
Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma
1997 · External reference
In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity
10.4049/jimmunol.160.9.4457 · 1998 · External reference
Targeting gene therapy vectors to CNS malignancies
10.3109/13550289809114514 · 1998 · External reference
Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells
10.1128/jvi.72.12.9683-9697.1998 · 1998 · External reference
HSV-1 gC modified with his-tag replacing heparan sulfate binding domain is expressed in an HSV-1 amplicon vector targeting system
1999 · External reference
Targeted adenoviral vectors for cancer gene therapy
10.1007/978-1-4615-5357-1_57 · 1998 · External reference
An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism
10.1128/jvi.72.12.9706-9713.1998 · 1998 · External reference
Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob
10.1128/jvi.72.3.1844-1852.1998 · 1998 · External reference
Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer
1998 · External reference
Targeted gene delivery by tropism-modified adenoviral vectors
10.1038/nbt1196-1574 · 1996 · External reference
Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor
1997 · External reference
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
10.1126/science.274.5286.373 · 1996 · External reference
Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
10.1128/jvi.72.12.9470-9478.1998 · 1998 · External reference
Structure and transcriptional regulation of the GFAP gene
10.1111/j.1750-3639.1994.tb00840.x · 1994 · External reference
Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RLi null mutant vector-potential glioblastoma targeting
10.1038/sj.gt.3300621 · 1998 · External reference
B-myc promoter retargeting of herpes simplex virus’ γ34.5-mediated virulence towards tumor and cycling cells
10.1128/jvi.73.9.7556-7564.1999 · 1999 · External reference
Transcriptional control by E2F
10.1006/scbi.1995.0013 · 1995 · External reference
Role of the retinoblastoma protein in the pathogenesis of human cancer
10.1200/jco.1997.15.11.3301 · 1997 · External reference
Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector
10.1038/nm1097-1145 · 1997 · External reference
Targeting gene expression to hypoxic tumor cells
10.1038/nm0597-515 · 1997 · External reference
Spatial and temporal control of gene therapy using ionizing radiation
10.1038/nm0895-786 · 1995 · External reference
GAL4-VP16 is an unusually potent transcriptional activator
10.1038/335563a0 · 1988 · External reference
GAL4 disrupts a repressing nucleosome during activation of GAL1 transcription in vivo
10.1101/gad.7.5.857 · 1993 · External reference
Development of an HSV-based vector for the treatment of Parkinson's disease
10.1006/exnr.1996.6395 · 1997 · External reference
In vivo transgene activation from an HSVbased gene therapy vector by GAL4:vpl6
1996 · External reference
The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor
10.1016/0092-8674(92)90234-4 · 1992 · External reference
A regulatory system for use in gene transfer
10.1073/pnas.91.17.8180 · 1994 · External reference
Drug inducible transgene expression in brain using a herpes simplex virus vector
10.1038/sj.gt.3300612 · 1998 · External reference
Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential
10.1093/nar/25.14.2723 · 1997 · External reference
Use of tetracycline-controlled gene expression systems to study mammalian cell cycle
10.1016/s0076-6879(97)83014-5 · 1997 · External reference
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
10.1073/pnas.89.12.5547 · 1992 · External reference
Transcriptional activation by tetracyclines in mammalian cells
10.1126/science.7792603 · 1995 · External reference
Inducible gene expression from defective herpes simplex virus vectors using the tetracycline-responsive promoter system
10.1016/0169-328x(96)00097-6 · 1996 · External reference
Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer
10.1038/sj.gt.3300487 · 1997 · External reference
HSV-1 infected-cell proteins influence the expression of a tetracycline-regulated transgene
1999 · External reference
Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7
10.1038/sj.cgt.7700003 · 1999 · External reference
Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, iron oxide particles to normal rat brain
1995 · External reference
Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption
10.1073/pnas.92.21.9829 · 1995 · External reference
Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms
10.1089/hum.1995.6.12-1543 · 1995 · External reference
Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector
1998 · External reference
Neural stem cells migrate throughout and express foreign genes within experimental gliomas—a potential gene therapy approach to brain tumors
1999 · External reference
C17-2 neural progenitor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas
1999 · External reference
